全文获取类型
收费全文 | 105篇 |
免费 | 16篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 4篇 |
口腔科学 | 1篇 |
临床医学 | 9篇 |
内科学 | 8篇 |
特种医学 | 3篇 |
外科学 | 2篇 |
综合类 | 22篇 |
预防医学 | 5篇 |
药学 | 29篇 |
中国医学 | 13篇 |
肿瘤学 | 31篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 9篇 |
2020年 | 11篇 |
2019年 | 5篇 |
2018年 | 2篇 |
2017年 | 4篇 |
2016年 | 5篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 10篇 |
2012年 | 4篇 |
2011年 | 8篇 |
2010年 | 7篇 |
2009年 | 5篇 |
2008年 | 4篇 |
2007年 | 6篇 |
2006年 | 3篇 |
2005年 | 4篇 |
2004年 | 1篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 2篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1994年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
排序方式: 共有128条查询结果,搜索用时 0 毫秒
1.
2.
3.
P.B. Soares T.S. Jeremias M. Alvarez-Silva M.A. Licínio M.C. Santos-Silva C.L. Vituri 《Brazilian journal of medical and biological research》2013,46(1):39-51
Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone marrow (BM). The aim of the present study was to evaluate the effects of IM on stromal and hematopoietic progenitor cells, specifically in the colony-forming units of granulocyte/macrophage (CFU-GM), using BM cultures from 108 1.5- to 2-month-old healthy Swiss mice. The results showed that low concentrations of IM (1.25 µM) reduced the growth of CFU-GM in clonogenic assays. In culture assays with stromal cells, fibroblast proliferation and α-SMA expression by immunocytochemistry analysis were also reduced in a concentration-dependent manner, with a survival rate of approximately 50% with a dose of 2.5 µM. Cell viability and morphology were analyzed using MTT and staining with acrydine orange/ethidium bromide. Most cells were found to be viable after treatment with 5 µM IM, although there was gradual growth inhibition of fibroblastic cells while the number of round cells (macrophage-like cells) increased. At higher concentrations (15 µM), the majority of cells were apoptotic and cell growth ceased completely. Oil red staining revealed the presence of adipocytes only in untreated cells (control). Cell cycle analysis of stromal cells by flow cytometry showed a blockade at the G0/G1 phases in groups treated with 5-15 µM. These results suggest that IM differentially inhibits the survival of different types of BM cells since toxic effects were achieved. 相似文献
4.
目的观察多西紫杉醇联合吡柔比星化疗在乳腺癌患者治疗中的效果,及对不良反应发生率的影响。方法选取乳腺癌患者为研究对象,并根据其化疗药物的不同分为对照组和观察组,对照组给予紫杉醇联合吡柔比星进行化疗,观察组给予多西紫杉醇联合吡柔比星进行化疗。观察2组患者的治疗效果、不良反应发生率和复发率,比较2组患者治疗前后肿瘤标志物水平的差异。结果观察组治疗有效率为97. 50%,明显高于对照组的80. 00%,差异有统计学意义(χ^2=6. 135,P=0. 013)。2组患者治疗前肿瘤标志物水平无差别,治疗后,观察组患者的CEA、CA125、CA153水平低于对照组(t=11. 432、18. 876、3. 703,P <0. 001)。2组患者骨髓抑制、恶心呕吐、脱发、中性粒细胞减少、肝功能损害等不良反应发生率无差别(χ^2=0. 238,P=0. 626)。对照组1年复发率较观察组高,但差异无统计学意义(χ^2=1. 053,P=0. 305)。结论多西紫杉醇联合吡柔比星化疗对乳腺癌患者的化疗效果较好,且不会增加骨髓抑制等不良反应发生率,具有良好的应用价值。 相似文献
5.
放射性核素靶向治疗是治疗恶性肿瘤及其他一些常见疾病的重要手段之一,但也有可能由于电离辐射生物效应同时造成骨髓抑制副反应.临床解决骨髓抑制的主要方法为口服或注射升白药物,最为常见的口服用药为利可君,化学性质独特,具有稳定升高白细胞水平以及一定的抗癌作用.在131Ⅰ治疗甲亢、甲状腺功能自主毒性腺瘤和大剂量131Ⅰ治疗甲癌术后残留、局部复发或远处转移的患者配合使用利可君可有效预防骨髓抑制或提高白细胞水平. 相似文献
6.
目的:探讨补肾解毒方对恶性肿瘤化疗中骨髓抑制的影响。方法:选择恶性肿瘤化疗患者152例为研究对象,以随机数字表法分组,分为观察组与对照组,各76例。对照组单纯接受常规化疗,观察组在常规化疗基础上口服补肾解毒中药复方制剂。对比两组患者两个化疗疗程完成率及第1疗程中血象情况。结果:观察组两个化疗疗程完成率为97.37%,显著高于对照组的84.21%(P<0.05);第1疗程化疗后1周、3周时,观察组各血象指标均高于对照组,差异有统计学意义(P<0.05)。结论:补肾解毒方可减轻恶性肿瘤化疗患者骨髓抑制,有助于骨髓造血功能恢复,提高化疗耐受性和成功率,值得临床推广。 相似文献
7.
F Oshita T Tamura H Okamoto T Miya A Kojima Y Ohe Y Sasaki K Eguchi T Shinkai N Saijo 《Japanese journal of clinical oncology》1991,21(5):353-359
The relation between degree of myelosuppression and episodes of infection was analyzed in 36 patients (92 treatment courses) with small cell lung cancer (SCLC) treated with intensive chemotherapy. The two regimens used were cisplatin (CDDP) + adriamycin (ADR) + cyclophosphamide (CPA) + etoposide (VP-16) + granulocyte-colony stimulating factor (G-CSF) and CDDP + teniposide (VM-26) + G-CSF, and they induced grade 3 or 4 leukopenia in 88% of treatment courses and febrile episodes in 60%. In the febrile courses, the mean nadirs of leukocyte and neutrophils (820 +/- 581/mm3, 101 +/- 267/mm3) were significantly longer (P less than 0.01) and the mean durations of grade 3 and 4 leukopenia and neutropenia significantly longer (P less than 0.001) than those of the non-febrile courses. It was noted, however, that febrile episodes appeared frequently in courses having the nadir of leukocytes below 1,000/mm3 (80%) or the nadir of neutrophils below 100/mm3 (74%). The administration of antibiotics was required for about 7 days to patients with febrile episodes. Sepsis was experienced in five courses, in which the neutrophils were all zero. All the patients, however, could be managed by an administration of antibiotics immediately after a febrile episode appeared, without delaying the subsequent chemotherapy except for one patient, who had had a performance status (PS) of 3 prior to chemotherapy. 相似文献
8.
9.
Song H Vita M Sallam H Tehranchi R Nilsson C Sidén A Hassan Z 《Cancer chemotherapy and pharmacology》2007,60(6):841-849
Myelosuppression is one the most frequent side effects of chemotherapy. New agents that more selectively target cancer cells
have been developed in attempt to improve the effects and to decrease the side effects of cancer treatment. Roscovitine is
a purine analogue and cyclin-dependent kinase inhibitor. Several studies have shown its cytotoxic effect in cancer cell lines
in vitro and in xenograft models in vivo. In this study, we investigated the effect of roscovitine on hematopoietic progenitors
in vitro and in vivo in mice. The clonogenic capacity of hematopoietic progenitors was studied using burst-forming unit-erythroid
(BFU-E), colony-forming unit granulocyte, macrophage (CFU-GM) and colony-forming unit granulocyte, erythroid, macrophage,
megakaryocyte (CFU-GEMM). In vitro, bone marrow cells were exposed to roscovitine (25–250 μM) in Iscove’s modified Dulbecco’s
media for 4 h or to roscovitine (1–100 μM) in MethoCult media for 12 days. No effect on colony formation was observed after
exposure to roscovitine for 4 h; however, concentration- and cell type-dependent effects were observed after 12 days. Roscovitine
in concentration of 100 μM inhibited the growth of all types of colonies, while lower concentrations have shown differential
effect on hematopoietic progenitors. The most sensitive were CFU-GEMM, followed by BFU-E and then CFU-GM. In vivo, mice were
treated with single dose of roscovitine (50, 100 or 250 mg/kg) and the effect on bone marrow was studied on day 1, 3, 6, 9
or 12 after the treatment. In the second part of experiment, the mice were treated with roscovitine 350 mg/kg/day divided
into two daily doses for 4 days. The bone marrow was examined on day 1 and 5 after the last dose of roscovitine. On day 1,
BFU-E decreased to less than 50% of the controls (P = 0.019). No decrease in BFU-E formation was observed on day 5. No significant effect was observed on CFU-GM and CFU-GEMM
growth after the treatment with multiple doses of roscovitine. Single doses of roscovitine or dimethylsulfoxide did not affect
the colony formation. We also studied the distribution of roscovitine to the bone marrow after a dose of 50 mg/kg was administered
intraperitoneally. Only 1.5% of the drug was detected in the bone marrow. Thus, the roscovitine effect on hematopoietic progenitors
in bone marrow in vivo is only transient. One reason may be that only a small fraction of roscovitine reaches the bone marrow.
Another explanation may be the short half-life observed for roscovitine that might not allow enough cell exposure to the drug.
However, the toxicity of roscovitine to hematopoietic progenitors in vitro is within the same exposure range as cytotoxicity
to cancer cells. Thus, precaution should be taken in clinical trials, especially when combinations with myelosuppressive cytostatics
are used.
Hairong Song and Marina Vita contributed equally to this work. 相似文献
10.
随着接受放疗患者生存期的延长,患者发生长期骨髓抑制的概率也大幅提高。长期骨髓抑制在临床中常被忽略,随着时间延长患者病情会逐渐加重,生活质量降低。许多长期骨髓抑制患者会形成再生障碍性贫血或者骨髓增生异常综合征,严重者可引发死亡。研究资料表明,活性氧和丝裂原活化蛋白激酶p38(P38MAPK)通路在辐射诱导长期骨髓抑制中占主要作用。笔者总结了辐射导致的长期骨髓抑制的相关研究,指出了今后的研究方向。 相似文献